RightFit
RecruitingPhase not listed

The CorEvitas Psoriasis (PSO) Registry

CorEvitas Psoriasis (PSO) Registry

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
18 Years and older
Sex
All sexes
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

  • Procedures mentioned: Questionnaires

Only what the study's summary and detailed description on ClinicalTrials.gov say. Time periods may describe the whole study or a part of it — ask the study team what applies to you.

Show the study's own words
  • "Longitudinal follow-up data is obtained via Corrona Questionnaires completed by both subjects and their treating dermatologists (also known as "Providers" for a Corrona registry study) every 6 months (+/- 30 days)."
  • "Any adverse events that are spontaneously volunteered by the subject or discovered as a result of general questioning by the investigator should be recorded on the Provider Follow-up Questionnaire for that visit."
Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study compares the safety of approved psoriasis treatments, including newer medicines, in everyday care. It is for adults in North America with psoriasis who are treated by skin doctors. It also tracks side effects, including cancer, and looks at how well treatments work.

The primary objective of the CorEvitas Psoriasis Registry is to study the comparative safety of approved psoriasis therapies in a North American cohort of psoriasis subjects treated by dermatologists. This includes assessing the incidence and nature of adverse events of special interest, including malignancy, in a real world population of psoriasis patients on new biologic therapies (e.g. secukinumab). Secondary objectives include analyzing the epidemiology and natural history of the disease, comorbidities, current treatment practices, and comparative effectiveness.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • Have psoriasis diagnosed by a dermatologist (skin doctor).
  • Be age 18 or older.
  • Be willing and able to give written consent to join.
  • Be willing and able to share personal information, including your full name and date of birth.
  • Have started or switched to a systemic psoriasis treatment (one that works throughout the body) within the past 12 months.

Who can't join

  • Be in, or plan to join, a psoriasis drug trial where treatment is assigned by chance and neither you nor the study team knows which treatment you get. You may still join another study that observes care or a later-stage trial where the treatment is known.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

ELIGIBILITY CRITERIA∗ To be eligible for enrollment into the CorEvitas Psoriasis Registry, a patient must satisfy all of the inclusion criteria and none of the exclusion criteria listed below. Inclusion Criteria: The patient must: 1. Have been diagnosed with psoriasis by a dermatologist. 2. Be at least 18 years of age or older. 3. Be willing and able to provide written consent for participation in the registry. 4. Be willing and able to provide Personally Identifiable Information (PII) that includes the following types of personal information at a minimum: 1) Full Name and 2) Date of Birth. 5. Meet one of the following criteria. Have started on or switched to a systemic psoriasis treatment within the previous 12 months†▲: Exclusion Criteria: 1\. Patient is participating in or planning to participate in a double-blind randomized of a psoriasis drug. Of note, concurrent participation in another observational registry or open-label Phase 3b/4 trial is not excluded.

Study sites (1)

MA